Drug firm Vivimed Labs today said it has inked pacts to acquire Hungary-based contract development and manufacturing firm Soneas for an undisclosed amount.
Vivimed Labs Spain S.L, the parent of Uquifa S.A has signed definitive agreements to facilitate the acquisition of Soneas, Vivimed Labs said in a BSE filing.
"The acquisition broadens Uquifa's market offering in the contract development and manufacturing organisation (CDMO) space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development," Vivimed Labs said.
Shares of Vivimed Labs today closed at Rs 67.80 per scrip on BSE, up 2.73 per cent from its previous close. PTI AKT.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)